Adding docetaxel to standard care improved failure-free survival and progression-free survival (PFS) but not overall survival, metastatic PFS, or prostate cancer-specific survival.
Investigators studied the effect of sequential valrubicin and docetaxel in patients with recurrent NMIBC following treatment with intravesical bacillus Calmette-Guérin and/or gemcitabine-docetaxel.
Adjuvant chemotherapy prolongs survival among patients with negative surgical margins regardless of number of positive lymph nodes.
A propensity-score matched comparison revealed no significant difference in oncologic outcomes between radical cystectomy and trimodal therapy.
Investigators sought to determine the efficacy and safety of N-803 plus BCG in patients with high-risk NMIBC.
However, a history of cancer more than one year before COVID-19 diagnosis not tied to increased mortality or hospitalization
Further studies are needed to evaluate oncologic outcomes after postoperative radiation therapy.
Investigators report a 24-month recurrence-free survival rate of 82% with the use of intravesical gemcitabine/docetaxel following complete transurethral resection of bladder tumor.
Investigators said the findings of their cross-sectional study “highlight the power as well as the limitations of prominent RCTs.”
Large differences in risks for severe adverse events according to sex seen for cancer patients receiving immunotherapy
